Topics 1. EVA-3S & Space-Bumps in the road presentation that you gave at TCT 2. CAPTURE 3500-Lesion morphology & Predictors for Stroke 3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.
by Heather Connelly, RN, BSN, EP Lab Manager, Riverside Methodist Hospital, Columbus, Ohio
In my time as the manager of a dynamic and lively EP lab at Riverside Hospital in Columbus, Ohio, I have learned many things. In my opinion, these are the five things that have contributed to our department’s success.
by Naga V.A. Kommuri, MD, E. Saulitis, PA-C, S.A. Mahmood, MD, M.I. Qureshi, MD, R. Rajagopal, MD, M.A. Siddiqui, MD; Sinai-Grace Hospital, Detroit, Michigan
This report describes two cases in which upper extremity vascular occlusion precluded sub-pectoral implantation, at which time the patient opted for the femoral approach. Previous literature describes successful follow-up periods of up to six months. This report documents long-term success of 21 months.
The U.S. Food and Drug Administration (FDA) approved the Xience™ V everolimus-eluting coronary stent system for the treatment of coronary artery disease. Xience V is the only drug-eluting stent to have demonstrated superiority over Boston Scientific’s Taxus® paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. Xience V will be launched in the United States immediately. Abbott also supplies a private-label version of Xience V to Boston Scientific called the Promus™ everolimus-eluting coronary stent system. Promus is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.
Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval of the Medtronic Attain StarFix® OTW (over-the-wire) lead (Model 4195). As the first active fixation left-heart lead for cardiac resynchronization therapy (CRT), the Attain StarFix lead has demonstrated a zero percent chronic dislodgement rate*.
Overall, including the acute dislodgements at one day post-implant, the lead has a low 0.7 percent dislodgement rate. These dislodgement rates are supported by one of the industry’s largest and longest-running left-heart lead clinical studies involving 385 implants followed for up to four years. Traditional passive fixation left-heart leads, where there is no active mechanism to fix the lead in place, show average dislodgement rates of 2-8 percent based on several published clinical studies.
The use of radio frequency identification devices appears to have the potential to cause critical care medical equipment to malfunction, according to a study in JAMA.
“Applications of autoidentification technologies such as radio frequency identification (RFID) in everyday life include security access cards, electronic toll collection, and antitheft clips in retail clothing. RFID applications in health care have received increasing attention because of the potentially positive effect on patient safety and also on tracking and tracing of medical equipment and devices. The current expenditure levels on RFID systems within health care in the United States are estimated to be approximately $90 million per year with 10-year growth projections to $2 billion,” the authors write.
Mobile EP Labs
I was wondering if anyone is aware of any functioning mobile EP labs? I have found little information on mobile electrophysiology laboratories. I am specifically wondering how one is set up, the cost to run a mobile lab, funding for the lab, and how staffing works for this type of facility.
—name withheld by request
(To reply to this question, please type “Mobile EP Labs” in your subject line.)
Your questions and/or responses in our email discussion group may be published in a future issue of EP Lab Digest. Please note that this Email Discussion Group is for medical professionals only.EP Lab Digest's Email Discussion Group does not provide medical advice, diagnosis or treatment.
NACCME.com is your one-stop source for continuing education. Browse through archived webcasts, journal articles, as well as upcoming live events and symposia at www.naccme.com/cardiology
Attention Readers: Practical EP addendum
The editors of Practical Electrophysiology would like to point out a correction made in Table 27.1 on page 210. Please note that this table heading should read "Table 27.1: Isoproterenol Infusion Rate (µg/min) for Single-Stage HUT”. Please make a note of it in your records that it should read micrograms, not milligrams. We sincerely regret the error.
by Tone M. Norekval, Chair of the Council on Cardiovascular Nursing and Allied Professions (CCNAP), European Society of Cardiology
Cardiovascular disease (CVD) is the main cause of death in the European Union, killing over 2 million people per year. These deaths cost the economy 301.5 billion U.S. dollars annually. Many of these deaths could be averted with proper prevention policies.
